Gene · 23532
PRAME: PRAME nuclear receptor transcriptional regulator
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PRAME: PRAME nuclear receptor transcriptional regulator. Genes, record 23532. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/23532
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P78395 | Melanoma antigen preferentially expressed in tumors | 509 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents285
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026209996 A1 | 2026-10-08 | 17 | P78395 | Espacenet |
| WO 2026210006 A1 | 2026-10-08 | 17 | P78395 | Espacenet |
| WO 2026190687 A1 | 2026-09-17 | 291 | P78395 | Espacenet |
| EP 4803546 A1 | 2026-09-09 | 38 | P78395 | Espacenet |
| WO 2026167100 A1 | 2026-08-13 | 79 | P78395 | Espacenet |
| JP 2026095514 A | 2026-06-11 | 943 | P78395 | Espacenet |
| JP 2026095514 A | 2026-06-11 | 944 | P78395 | Espacenet |
| JP 2026095514 A | 2026-06-11 | 945 | P78395 | Espacenet |
| JP 2026095514 A | 2026-06-11 | 946 | P78395 | Espacenet |
| JP 2026095514 A | 2026-06-11 | 947 | P78395 | Espacenet |
1 to 10 of 285
See all 285 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants729
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PRAME papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 31 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 16 | 2025 |
| P30EY014801 | Miami Center for Vision Research | 14 | 2025 |
| P50CA126752 | SPORE in Lymphoma | 14 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 10 | 2025 |
| P01CA018029 | Adult Leukemia Research Center | 6 | 2025 |
| P30CA240139 | The Sylvester Cancer Center Support Grant | 6 | 2025 |
| P30CA142543 | UT Southwestern Medical Center Simmons Comprehensive Cancer Center | 5 | 2025 |
| P30EY026877 | Stanford Vision Research Core | 5 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 5 | 2025 |
1 to 10 of 729Source NIH's project files
See all 729 nih grantsPapers1,874
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular Characterization of Sclerosing Nevi With Pseudomelanomatous Features. | J Cutan Pathol | 2026 | 42816143 | PubTator, text mining | PubMed |
| Papillary endothelial hyperplasia in late post-radiation or late post-operative breast hematomas mimicking angiosarcoma. | Hum Pathol | 2026 | 42815784 | PubTator, text mining | PubMed |
| Search for leukemia-restricted targets: a new paradigm for precision immunotherapy in acute myeloid leukemia. | Haematologica | 2026 | 42779343 | PubTator, text mining | PubMed |
| Immunohistochemical Predictors in Head and Neck Mucosal Melanoma. | Head Neck Pathol | 2026 | 42771296 | PubTator, text mining | PubMed |
| PRAME as a Diagnostic Adjunct in Clear Cell Sarcoma. | Appl Immunohistochem Mol Morphol | 2026 | 42746728 | PubTator, text mining | PubMed |
| Performance of PRAME Immunohistochemistry in Distinguishing Classic Hodgkin Lymphoma from Anaplastic Large Cell Lymphoma and T-Cell Lymphoma. | Cancers (Basel) | 2026 | 42738395 | PubTator, text mining | PubMed |
| Top advances of the year in autologous cellular therapy in melanoma and solid tumors. | Cancer | 2026 | 42734903 | PubTator, text mining | PubMed |
| Histopathologic, Genomic, and Clinical Characteristics of Primary Cutaneous Melanocytic Tumors With Concomitant NRAS Q61 and IDH1 R132C Mutations. | Mod Pathol | 2026 | 42710739 | PubTator, text mining | PubMed |
| Sentinel lymph node biopsy in melanoma: pathologic evaluation and diagnostic considerations. | J Pathol Transl Med | 2026 | 42675997 | PubTator, text mining | PubMed |
| Integrated Immunotherapy Target Atlas for Ewing Sarcoma. | Cancer Genomics Proteomics | 2026 | 42674817 | PubTator, text mining | PubMed |
1 to 10 of 1,874
See all 1,874 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/23532
GET https://conductscience.org/api/genes/v1/23532/patents?page=2